Impulse Dynamics Appoints Five New Board Members
New Directors Bring a Wealth of Relevant Experience
MARLTON, N.J., November 11, 2021 — Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders.
“We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors,” said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics. “This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and most of all, for patients.”
“The extremely relevant and varied achievements of our new Board members will benefit us for many years to come,” said Dr. Simos Kedikoglou, CEO of Impulse Dynamics. “The depth and breadth of their experience, both with public companies in general and medical technologies specifically, will be an enormous benefit to Impulse Dynamics. Their presence will dramatically enhance our ability to execute on the opportunities before us with a collective set of experiences that is second to none.”
James R. Tobin serves on the Boards of TransMedics, Inc. (Nasdaq: TMDX), where he is also Chairman, and Globus Medical, Inc. (NYSE: GMED). Jim previously served as President and Chief Executive Officer of Boston Scientific (NYSE: BSX) and Biogen (Nasdaq: BIIB), Chief Operating Officer of Baxter (NYSE: BAX), and was a lieutenant in the U.S. Navy. Jim holds an MBA from Harvard Business School and a bachelor’s degree from Harvard College.
Joseph H. Capper most recently served as President and Chief Executive Officer of BioTelemetry, Inc, (formerly Nasdaq: BEAT), the successor to CardioNet, Inc., and Home Diagnostics, Inc. (Nasdaq: HDIX). Prior to Home Diagnostics, Joe was President and Chief Executive Officer of CCS Medical Inc., a private company. Earlier, Joe spent nine years with Bayer Corporation, ultimately becoming National Sales Director of the Diabetic Products Division, where he led a 180-person sales organization with responsibility for over $350 million in revenue. Joe also has a distinguished service record, having served in the U.S. Navy as a combat aviator and later as a congressional liaison. Joe received his undergraduate degree in accounting from West Chester University and an MBA in International Finance from George Washington University.
Glenn P. Muir, a certified public accountant, was Chief Financial Officer of Hologic, Inc. (Nasdaq: HOLX) for twenty-six years, including the Company’s IPO in 1990. Glenn is currently a member of the Board of Directors and is the Audit Committee Chair at Repligen Corporation (Nasdaq: RGEN), Neuronetics, Inc. (Nasdaq: STIM), and at G1 Therapeutics, Inc. (Nasdaq: GTHX). His past board experience includes RainDance Technologies, Inc., Hologic, Inc. (Nasdaq: HOLX), ReWalk Robotics Ltd (Nasdaq: RWLK), and Vivid Technologies (Nasdaq: Vivid), Inc. Glenn graduated from the University of Massachusetts in Amherst and holds an MBA from Harvard University Graduate School of Business Administration and a master’s degree in taxation from Bentley College Graduate School of Business.
John Bakewell has served in senior executive roles for nearly three decades, building and executing business strategies for growth companies across the medical device, specialty pharma, diagnostics, and healthcare provider sectors while also serving on public and private company boards. He currently serves on the Boards of Directors of Treace Medical Concepts, Inc. (Nasdaq: TMCI), Neuronetics, Inc. (Nasdaq: STIM), and Xtant Medical Holdings (NYSE American: XTNT), and previously served on the Boards of Entellus Medical, Inc. (Nasdaq: ENTL), ev3, Inc. (Nasdaq: EVVV), Corindus Vascular Robotics, Inc. (Nasdaq: CVRS), and Keystone Dental, Inc. John served as Executive Vice President and Chief Financial Officer of Wright Medical Group, Inc. (Nasdaq: WMGI); Vice President, Finance and Administration and CFO of Cyberonics Inc. (Nasdaq: CYBX); Chief Financial Officer of Lantheus Holdings, Inc. (Nadaq: LNTH); Executive Vice President and Chief Financial Officer of RegionalCare Hospital Partners, Inc.; and Chief Financial Officer of Exact Sciences Corporation (Nasdaq: EXAS). Mr. Bakewell began his career as a CPA, serving with KPMG and Ernst & Young. He holds a bachelor’s degree in accounting from the University of Northern Iowa and is a certified public accountant (inactive).
Daniel Scavilla is the Executive Vice President, Chief Commercial Officer and President, of Trauma at Globus Medical, Inc. (NYSE: GMED) where he previously served as Senior Vice President and Chief Financial Officer. Previously, he spent 28 years in various financial management positions at Johnson & Johnson (JNJ), including as CFO, Global Vice President Finance & Business Operations at JNJ’s Vision Care Division, and as Worldwide Vice President Finance of the Advanced Sterilization Products division of JNJ. Mr. Scavilla received a bachelor’s degree in finance from LaSalle University and holds an MBA in International Management from Temple University.
About the Optimizer® Integra CCM-D™ System and CCM® Therapy
The Optimizer Integra CCM-D System is an investigational device that combines CCM therapy and ICD therapy into one device. This device is being used in an FDA-approved Investigational Device Exemption (IDE) study and is not available for sale in the United States.
Impulse Dynamics currently offers the Optimizer system that is FDA-approved and CE-marked. The Optimizer system delivers CCM therapy — the company’s proprietary technology — to the heart. CCM therapy has been designed by Impulse Dynamics to improve the heart’s contraction, allowing more oxygen-rich blood to be pushed out through the body. CCM therapy is indicated to improve the 6-minute hall walk, quality of life, and functional status of NYHA Class III heart failure patients who remain symptomatic despite guideline-directed medical therapy, are not indicated for CRT, and have a left ventricular ejection fraction ranging from 25 to 45 percent.
CCM therapy delivers non-excitatory electrical pulses from the implantable Optimizer device in a manner designed to improve heart contraction. CCM therapy sends unique electrical pulses to the heart cells during their absolute refractory period. Impulse Dynamics has completed numerous clinical studies, including several randomized controlled trials, and CCM therapy has been published in more than 120 peer-reviewed journal articles.
About Impulse Dynamics
Impulse Dynamics is dedicated to advancing the treatment of heart failure for patients and the healthcare providers who care for them. The company pioneered its proprietary CCM therapy, which uses the Optimizer technology platform to improve quality of life in heart failure patients. CCM therapy is delivered through the Optimizer system, which includes an IPG implanted in a minimally invasive procedure and approved for commercial use in the United States and 44 countries worldwide. More than 9,000 patients have received the therapy as part of clinical trials and real-world use, where it is proven to be safe and effective for heart failure patients with debilitating symptoms who otherwise have few effective options available to them. To learn more, visit www.ImpulseDynamics.com, or follow the company on LinkedIn, Twitter, and Facebook.
This press release contains forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential’’ or ‘‘continue’’ or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning potential benefits of CCM therapy, and CCM therapy combined with an ICD delivered via a single device (CCM-D), and the absence of risks associated therewith; the ability for CCM therapy and our products to fill a significant unmet medical need for patients with heart failure; and the short-term and long-term benefits of the Optimizer Integra CCM-D System and CCM therapy in patients with heart failure, as well as to the physicians treating those patients. These forward-looking statements are based on management’s current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release include, without limitation: the company’s future research and development costs, capital requirements and the company’s needs for additional financing; commercial success and market acceptance of CCM therapy; the company’s ability to achieve and maintain adequate levels of coverage or reimbursement for Optimizer systems or any future products the company may seek to commercialize; competitive companies and technologies in the industry; the company’s ability to expand its indications and develop and commercialize additional products and enhancements to its current products; the company’s business model and strategic plans for its products, technologies and business, including its implementation thereof; the company’s ability to expand, manage and maintain its direct sales and marketing organization; the company’s ability to commercialize or obtain regulatory approvals for CCM therapy and its products, or the effect of delays in commercializing or obtaining regulatory approvals; FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the United States and international markets; the timing or likelihood of regulatory filings and approvals; and the company’s ability to establish and maintain intellectual property protection for CCM therapy and products or avoid claims of infringement. The company does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date of this press release.
Impulse Dynamics (USA), Inc.
50 Lake Center Executive Park, 401 Route 73 N, ‐ Building 50 Suite 100
Marlton, NJ 08053
Phone: (856) 642‐9933